Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Santos-Alarcón S.
  • Sahuquillo-Torralba A.
  • Rivera-Díaz R.
  • Belinchón-Romero I.
  • Ruiz-Genao D.
  • Romero-Maté A.
  • Ruiz-Villaverde R.
  • Ferran-Farrés M.
  • Gallardo-Hernández F.
  • Almenara-Blasco M.
  • Suarez-Perez J.A.
  • González-Cantero Á.
  • Martínez-Lorenzo E.
  • Fernández-Armenteros J.M.
  • del Alcázar-Viladomiu E.
  • García-Latasa J.
  • Rocamora-Durant V.
  • Ara-Martín M.
  • Mateu-Puchades A.
  • Llamas-Velasco M.
  • Vilarrasa E.
  • Velasco-Pastor M.
  • De la Cueva P.
  • Carrascosa J.M.
  • Magdaleno-Tapial J.

Abstract

BACKGROUND AND OBJECTIVE: Risankizumab - a humanized monoclonal antibody that targets the p19 subunit of IL-23 - has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. OBJECTIVE: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice. METHODS: This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52. RESULTS: A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7±14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30kg/m(2)). The mean baseline PASI score was 11.4±7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI =2 was greater in the group with a BMI =30kg/m(2) on weeks 4 (P=.04), 16 (P=.001), and 52 (P=.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P=.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P=.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment. CONCLUSIONS: Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.

Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
125-133
PubMed:
38452889
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 4

Citas Recibidas en Scopus: 4

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Anticuerpo monoclonal; Datos del mundo real; Monoclonal antibody; Psoriasis; Psoriasis Area and Severity Index (PASI); Real-world data; Risankizumab; Índice de Área y Severidad de la Psoriasis (PASI)

Cita

Compartir